SBIO ALPS Medical Breakthroughs ETF

ALPS Medical Breakthroughs ETF

As of

Market Price

NAV
|

NAV Change

Daily Return

Net Assets

YTD Return

Dividend Yield
research-concept

SBIO Monthly Insights

Explore a deep dive review of SBIO's performance, contribution to return, valuation and key takeaways from October 2022.

Overview

   Investment Objective

The ALPS Medical Breakthroughs ETF (SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI).

   Strategy

The ALPS Medical Breakthroughs ETF (SBIO) provides exposure to small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the US Food and Drug Administration clinical trials. Constituents must have a market capitalization of no less than $200 million and no more than $5 billion.

Fund Details

 
Ticker
Listing Exchange
NYSE Arca
CUSIP
ISIN
Net Assets
as of
Inception Date
Fund Type
Exchange-Traded Fund
Primary Benchmark
S-Network Medical Breakthroughs Index
← Swipe to see additional data →

Performance and Fees

Returns

As of

Total Returns
← Swipe to see additional data →

As of

Total Returns
← Swipe to see additional data →

As of

← Swipe to see additional data →

Performance data quoted represents past performance. Past performance is no guarantee of future results so that shares, when redeemed, may be worth more or less than their original cost. The investment return and principal value will fluctuate. Current performance may be higher or lower than the performance quoted. Performance includes reinvested distributions and capital gains.

Market Price is based on the midpoint of the bid/ask spread at 4 p.m. ET and does not represent the returns an investor would receive if shares were traded at other times.

Fund inception date: 12/30/2014

S-Network Medical Breakthroughs Index: comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the US Food and Drug Administration (“FDA”) clinical trials.

NASDAQ Biotechnology Index: designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index.

One may not invest directly in an index.

$10,000 Hypothetical Investment

The chart above represents the total return historical performance of a hypothetical investment of $10,000 in the Fund over the life of the Fund. Performance calculations are as of the end of each month. Past performance is no guarantee of future results. This chart does not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.

Fees

As of
 
← Swipe to see additional data →

Facts and Characteristics

Fund Pricing

As of

Market Price
NAV
NAV Change
Premium/Discount
Premium/Discount Difference
Daily Return
YTD Return
Last Trade Price (EOD)
Intraday (Midpoint) Price
as of as of
Total Market Value
 
* During market trading hours, intraday price is up to a 15 minute delay.
← Swipe to see additional data →
Trading Characteristics

As of

Shares Outstanding
Average 30-Day Volume
Daily Volume
as of
Dollar Volume
Net Create/Redeems
30-Day Median Bid/Ask Spread




 
* During market trading hours, daily volume is up to a 15 minute delay.
Fund Yields


Dividend Yield
30-Day SEC Yield
30-Day SEC Yield (Unsubsidized)
Trailing Twelve Month Yield
← Swipe to see additional data →
 

Dividend Yield: a financial ratio that shows how much a Fund pays out in dividends each year relative to its share price.

30-Day SEC Yield: reflects the dividends and interest earned during the period, after the deduction of the Fund's expenses.

30-Day SEC Yield (Unsubsidized): reflects the dividends and interest earned during the period, after the deduction of the Fund’s expenses, excluding fee waivers.

Trailing Twelve Month Yield: refers to the percentage of income a portfolio has returned to investors over the last 12 months.

Risk Metrics

For the 3 years ending

Standard Deviation
Sharpe Ratio
Sortino Ratio
Fund vs Index1 Fund vs Index2
Alpha
Beta
R-Squared
Tracking Error
Upside Capture
Downside Capture
1  
2  
← Swipe to see additional data →

Portfolio

Sector Breakdown

As of

Geography Breakdown

As of

Fund Holdings

← Swipe to see additional data →
← Swipe to see additional data →

Distributions

Fund Distributions

Distribution Frequency: Annually
Ex-Date Record Date Payable Date STCG LTCG Return of Capital Qualified Dividend Ordinary Income Income Total Section 19a
← Swipe to see additional data →
No distribution information at this time.
Document Name Date Document Category Document Type Download
ALPS Medical Breakthroughs ETF Monthly Insights - October 2022 10/31/2022 Literature Insight
ALPS Medical Breakthroughs ETF Fact Sheet 09/30/2022 Literature Fact Sheet
Thematic ETF Supersleeve 09/30/2022 Literature Brochure
What is Thematic Investing? 09/30/2022 Literature Slick
ETF Offerings 09/30/2022 Literature Fund List
ALPS Medical Breakthroughs ETF Monthly Insights - September 2022 09/30/2022 Literature Insight
ALPS ETF Trust 3rd Fiscal Quarter Holdings 08/31/2022 Regulatory 3rd Fiscal Quarter Holdings
ALPS Thematic ETFs Semi-Annual Report 05/31/2022 Regulatory Semi-Annual Report
ALPS ETF Trust Statement of Additional Information 03/31/2022 Regulatory Statement of Additional Information
ALPS Medical Breakthroughs ETF Statutory Prospectus 03/31/2022 Regulatory Statutory Prospectus
ALPS Medical Breakthroughs ETF Summary Prospectus 03/31/2022 Regulatory Summary Prospectus
ALPS ETF Trust 1st Fiscal Quarter Holdings 02/28/2022 Regulatory 1st Fiscal Quarter Holdings
ALPS Thematic ETFs Annual Report 11/30/2021 Regulatory Annual Report

Funds Related to SBIO

ACES

ALPS Clean Energy ETF

Learn More About ACES

DTEC

ALPS Disruptive Technologies ETF

Learn More About DTEC

JRNY

ALPS Global Travel Beneficiaries ETF

Learn More About JRNY

Fund Disclosure

Shares are not individually redeemable. Investors buy and sell shares on a secondary market. Only market makers or “authorized participants” may trade directly with the Fund, typically in blocks of 5,000, 25,000 or 50,000 shares.

The Fund’s investments are concentrated in the pharmaceuticals and biotechnology industries, and underperformance in these areas will result in underperformance in the Fund. Investments in small and micro capitalization companies are more volatile than companies with larger market capitalizations. Companies in the pharmaceuticals and biotechnology industry may be subject to extensive litigation based on product liability and similar claims. Legislation introduced or considered by certain governments on such industries or on the healthcare sector cannot be predicted.

Companies in the pharmaceuticals industry are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. The profitability of some companies in the pharmaceuticals industry may be dependent on a relatively limited number of products. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the pharmaceuticals industry are subject to government approvals, regulation and reimbursement rates. The process of obtaining government approvals may be long and costly. Many companies in the pharmaceuticals industry are heavily dependent on patents and intellectual property rights. The loss or impairment of these rights may adversely affect the profitability of these companies. 

The development of new drugs generally has a high failure rate, and such failures may negatively impact the stock price of the company developing the failed drug. Biotechnology companies may have persistent losses during a new product’s transition from development to production. In order to fund operations, biotechnology companies may require financing from the capital markets, which may not always be available on satisfactory terms or at all.

The Fund is considered nondiversified and as a result may experience greater volatility than a diversified fund. 

The Fund employs a “passive management” - or indexing - investment approach and seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index. Unlike many investment companies, the Fund is not “actively” managed. Therefore, it would not necessarily sell or buy a security unless that security is removed from or added to the underlying index, respectively.

ALPS Portfolio Solutions Distributor, Inc. is the distributor for the Fund.